HC Wainwright Issues Negative Outlook for Myomo Earnings

Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) - Analysts at HC Wainwright reduced their Q2 2025 EPS estimates for Myomo in a research report issued to clients and investors on Thursday, May 8th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of ($0.11) per share for the quarter, down from their previous forecast of ($0.06). HC Wainwright currently has a "Buy" rating and a $9.50 price objective on the stock. The consensus estimate for Myomo's current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo's Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.10 EPS, FY2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.08) EPS, FY2026 earnings at $0.06 EPS and FY2027 earnings at $0.25 EPS.

MYO has been the subject of several other reports. Alliance Global Partners restated a "buy" rating on shares of Myomo in a research report on Tuesday, March 11th. Ascendiant Capital Markets raised their target price on Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a report on Monday, March 17th. Finally, Craig Hallum reduced their target price on Myomo from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $9.50.

Myomo Price Performance

Shares of NYSEAMERICAN:MYO traded up $0.06 during trading on Monday, reaching $3.25. 717,987 shares of the company traded hands, compared to its average volume of 367,513. The company has a market capitalization of $98.31 million, a price-to-earnings ratio of -14.13 and a beta of 1.68. The business's 50 day moving average price is $4.69. Myomo has a 52 week low of $2.76 and a 52 week high of $7.17.

Institutional Investors Weigh In On Myomo

Several institutional investors and hedge funds have recently added to or reduced their stakes in MYO. Barclays PLC bought a new position in Myomo during the third quarter valued at about $36,000. BNP Paribas Financial Markets purchased a new position in Myomo in the fourth quarter valued at about $64,000. Walleye Capital LLC bought a new position in shares of Myomo during the 4th quarter valued at approximately $66,000. Squarepoint Ops LLC bought a new position in shares of Myomo during the 4th quarter valued at approximately $74,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Myomo during the 4th quarter worth approximately $95,000. Hedge funds and other institutional investors own 44.99% of the company's stock.

Insiders Place Their Bets

In other Myomo news, Director Thomas F. Kirk acquired 7,400 shares of the company's stock in a transaction on Thursday, March 13th. The shares were purchased at an average cost of $5.00 per share, with a total value of $37,000.00. Following the completion of the purchase, the director now owns 255,933 shares of the company's stock, valued at approximately $1,279,665. This represents a 2.98% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Harry Kovelman sold 30,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.50, for a total transaction of $165,000.00. Following the completion of the sale, the insider now owns 97,973 shares in the company, valued at $538,851.50. This represents a 23.44% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.54% of the company's stock.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.